Published • loading... • Updated
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026
Summary by Mt. Airy News
8 Articles
8 Articles
Appalachian News-Express+7 Reposted by 7 other sources
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026
GUANGZHOU, China, Oct. 24, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, today announced the presentation of clinical data for BAT8008, a TROP2-targeted antibody-drug conjugate (ADC), in combination with BAT1308, an anti-PD-1…
Coverage Details
Total News Sources8
Leaning Left2Leaning Right0Center4Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 33%
C 67%
Factuality
To view factuality data please Upgrade to Premium
